

LEMBASE (Embase[™] Learning Database)

- Subject Coverage**
- Alternative medicine
 - Biological science relevant to human medicine
 - Biochemistry
 - Biomedical engineering and medical instrumentation
 - Biotechnology
 - Clinical and experimental medicine
 - Drugs
 - Environmental science
 - Forensic science
 - Hospital management
 - Industrial medicine
 - Medical devices
 - Occupational hygiene
 - Pediatrics
 - Pharmacy
 - Pharmacology and drug therapy
 - Pharmaco-economics
 - Public health

File Type Bibliographic, Learning

Features

Thesaurus	Controlled Term (/CT)			
Alerts (SDIs)	None			
CAS Registry Number[®] Identifiers	<input checked="" type="checkbox"/>	Page Images	<input type="checkbox"/>	STN [®] AnaVist [™] <input type="checkbox"/>
Keep & Share	<input checked="" type="checkbox"/>	SLART	<input checked="" type="checkbox"/>	STN Easy [®] <input type="checkbox"/>
Learning Database	<input checked="" type="checkbox"/>	Structures	<input type="checkbox"/>	

- Record Content**
- Bibliographic information
 - Controlled terms (Emtree drug and medical descriptors)
 - Drug trade names and their manufacturers
 - Medical device trade names and manufacturers (1998 to the present)
 - Approximately 80% of the records include abstracts
 - CAS Registry Numbers

File Size 21,796 (3/2017)

Coverage Selected records from 1947-2013

Updates None

Language English

Database Producer

<p>In North America: Elsevier B.V. Bibliographic Databases 360 Park Avenue South New York, NY 10010-1710 Phone: 212-989-5800 Fax: 212-633-3990 Email: usembaseinfo@elsevier.com</p>	<p>In Europe and Rest of World (outside Japan): Elsevier B.V. E-products Team Radarweg 29 Amsterdam 1043 NX Netherlands Phone: (+31) 20 485 3911 Fax: (+31) 20 485 2912 Email: ebd-marketing@elsevier.com</p>	<p>In Japan: Elsevier B.V. Bibliographic Databases 1-9-15 Higashi-Azabu Minato-ku Tokyo 106-0044 Japan Phone: (+81)-3-5561-5031 Fax: (+81)-3-5561-5046 Email: jpembaseinfo@elsevier.com</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sources More than 7,600 journals from about 70 countries (approximately 95% of file)
Books, conference proceedings, and reports (approximately 5% of file)

User Aids

- Online Helps (HELP DIRECTORY lists all help messages available)
- STNGUIDE
- Embase Journal List is available at: <http://www.embase.com/info/>
- Emtree Thesaurus (updated three times per year)

Clusters

- LEARNING

[STN Database Clusters](#) information (PDF).

Pricing Enter HELP COST at an arrow prompt (=>).

Search and Display Field Codes

The fields that allow left truncation are marked with an asterisk (*).

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index * (contains single words from the title (TI), abstract (AB), controlled term (CT), chemical name (CN), corporate name (CO), name of product (NP), and gene number (GEN) fields, as well as CAS Registry Numbers)	None (or /BI)	S STOMACH ULCER S 51481-61-9 S FOOD(1W)DRUG ADMINISTR? S ?SPRAY?	AB, CN, CO, CT, GEN, NP, RN, TI
Abstract *	/AB	S IMAGING STUD?/AB S ?PHYSEM?/AB	AB
Accession Number	/AN	S 85114254/AN S 2005469912/AN	AN
Author (includes editor) (6)	/AU	S JONES, E A/AU S O REILLY?/AU	AU, SO
Chemical Name (Drug or Medical Device Trade Name) (1,2)	/CN (or /TN)	S TAGAMET/CN S NEMBUTAL/CN (L) LABAZ/CO	CN
Chemical Name Segment *	/CNS	S THIOL/CNS	
Clinical Trial Numbers	/NCT	S NCT00004730/NCT S ISRCTN78047760/NCT	NCT
Controlled Term (contains Medical Descriptors, Drug Descriptors, including major terms, and EMTREE codes) (3)	/CT	S STOMACH ULCER/CT (L) DT/CT S *STOMACH ULCER/CT S LINDANE+ALL/CT S CISPLATIN/CT (L) IT/CT S PANCREAS DISEASE/CT S ANIMAL EXPERIMENT/CT AND L1	CT
Corporate Name (Manufacturer)(2,4)	/CO	S CALBIOCHEM/CO S RESEARCH BIOCHEMICALS/CO	CO
Corporate Source (4,6)	/CS	S UNIV ARIZ?/CS	CS
Country of Publication (ISO code and text)	/CY	S FRANCE/CY S JP/CY	CY
Digital Object Identifier	/DOI (or /FTDOI)	S 10.1016?/DOI	FTDOI, DOI
Document Number	/DN	S 46328220/DN	DN
Document Type (code and text)	/DT (or /TC)	S CONFERENCE/DT S C/DT	DT
Email Address (4)	/EML	S SANDHOFF@UNI-BONN.DE/EML S SANDHOFF DE/EML	CS, EML
Entry Date (5,7)	/ED	S ED>20041100	ED
Entry Date First Appeared in Embase or Embase Alert (EMBAL) (5)	/ED.FIR	S ED.FIR>20130500	ED.FIR, ED
Entry Date MEDLINE (5,7)	/EDAL	S L1 and EDAL>20080100	ED
Field Availability	/FA	S L2 AND AB/FA	Not displayed
File Segment (code and text)	/FS	S 016/FS S CANCER/FS S CLASSIC/FS S MEDLINE/FS	FS
Gene Number	/GEN	S A02168/GEN	GEN
International Standard (Document) Number (ISBN, ISSN, CODEN)	/ISN	S LANCAO/ISN S 0388-6107/ISN S 0444810153/ISN	ISN, SO
Journal Title (contains full and abbreviated title)	/JT	S J CARD SURG/JT S JOURNAL OF CARDIAC SURGERY/JT	JT, JTA, JTF, SO
Language (ISO code and text)	/LA	S L1 AND EN/LA	LA
Meeting Date	/MD	S 20090822/MD	MD, SO
Meeting Information	/MT	S MARROW/MT	MT, SO
Meeting Location	/ML	S JAPAN/ML	ML, SO
Meeting Organizer	/MO	S AMGEN/MO	MO, SO
Meeting Year	/MY	S 2009/MY	MY, SO

Search and Display Field Codes (cont'd)

Search Field Name	Search Code	Search Examples	Display Codes
Name of Product	/NP	S ACUSON 128?/NP	NP
Publication Date (5)	/PD	S 20040100-20050600/PD	PD, SO
Publication Year (5)	/PY	S 2003-2004/PY	PY, SO
Publisher	/PB	S ELSEVIER IRELAND/PB	PB
Publisher Item Identifier	/PUI	S "S 0001-706X(96)00022-8"/PUI	PUI
Source (contains abbreviated journal title, publication date, collation information (volume, issue, pagination, and number of references), meeting information, ISSN, ISBN, and CODEN)	/SO	S HEMATOL PATHOL/SO S (1011-6788 AND 2004)/SO	SO
Summary Language (ISO code and text)	/SL	S L3 AND EN/SL	SL
Supplementary Terms *	/ST	S HIPPOCAMPUS/ST	ST
Title *	/TI	S AMINO ACID#/TI	TI
Update Date (5,8)	/UP	S UP20050119	ED
Update Date MEDLINE (5,8)	/UPAL	S L1 and UPAL>20080100	ED

- (1) Medical device trade names are available from 1998 to the present.
- (2) For data after mid-1998, you can use the (L) operator to link the trade names in /CN to manufacturer names in /CO.
- (3) An online thesaurus is available in this field.
- (4) Search with implied (S) proximity is available in this field.
- (5) Numeric search field that may be searched with numeric operators or ranges.
- (6) Use (L) to link AU CS pairs.
- (7) ED is the entry date for Elsevier-created Embase records and specifically excludes records from the MEDLINE file segment. EDAL is used for the entry date of Embase records plus MEDLINE file segment records.
- (8) UP is the update date for Elsevier-created Embase records and specifically excludes records from the MEDLINE file segment. UPAL is used for the update date of Embase records plus MEDLINE file segment records.

Limiting Search Codes

Only an L-number for an answer set created in EMBASE may be limited.

Search Field Name	Search Code (1)	Search Examples
Animal subject	/NONHUMAN	S L4/NON
English language records	/ENGLISH	S L1/MAJ,ENG (2)
Female subject	/FEMALE	S L3/FEM
Human subject	/HUMAN	S L1/HUM
Major descriptor	/MAJOR	S L1/MAJ (3)
Male subject	/MALE	S L2/MAL

- (1) The code may be abbreviated to the first three letters.
- (2) An answer set may be limited to more than one subject area.
- (3) Major terms may be searched directly in the Controlled Term (/CT) field by preceding the search term with an asterisk, e.g., S *LUNG EMBOLISM/CT.

Super Search Fields

Enter a super search code to execute a search in one or more fields that may contain the desired information. Super search fields facilitate crossfile and multifile searching. EXPAND may not be used with super search fields. Use EXPAND with the individual field codes instead.

Search Field Name	Search Code	Fields Searched	Search Examples	Display Codes
Index Terms	/IT	/CT, /ST	S ANIMAL EXPERIMENT/IT	CT, ST

Controlled Term (/CT) Thesaurus

All relationship codes may be used with both the SEARCH and EXPAND command in the Controlled Term (/CT) thesaurus.

Code	Content	Example
ALL	All associated terms (BT, SELF, QA, TYPE, NTYP, HNTE, RN, EC, UF, NT)	E JOINT INJURY+ALL/CT E LINDANE+ALL/CT
AUTO (1)	Automatic Relationship (SELF, USE)	E ARTICULAR TRAUMA+AUTO/CT
BT	Broader Terms (BT, SELF)	E ANEURYSM+BT/CT
HIE	Hierarchy (Broader and Narrower Terms) (BT, SELF, NT)	E MYOPATHY+HIE/CT
KT	Keyword Terms (multiword phrases containing term) (SELF, KT)	E LYMPHOMA+KT/CT
NOTE	Notes associated with the term (SELF, NOTE, HNTE, RN, EC)	E VIRILIZATION+NOTE/CT
NT	Narrower Terms (SELF, NT)	S STOMACH DISEASE+NT/CT
PFT	Preferred Terms and Synonyms (SELF, USE, UF)	S SCLEROTHROMBOSIS+PFT/CT S ALPHA AMYLASE + PFT/CT
STD	Standard (Broader and Narrower Terms) (BT, SELF, NT)	E KIDNEY FAILURE+STD/CT
UF	Used For (Synonyms) (Forbidden Terms) (SELF, UF)	E ASPARAGINE+UF/CT
USE	Use (Preferred Terms) (SELF, USE)	E ARTICULAR TRAUMA+USE/CT

(1) Automatic relationship is SET OFF. When SET REL is ON, the result of EXPAND without any relationship code is the same as described for AUTO.

Thesaurus Field Descriptors

Code	Description
→	Self
BT	Broader Term
EC	Enzyme Commission Number
HNTE (1)	History Note
KT	Keyword Term
NT	Narrower Term
NTYP (2)	Term Name Type
QA	Subheading abbreviation
RN	CAS Registry Number
TYPE (3)	Term Type
UF	Used For Term (Synonym)
USE	Use (Preferred) Term

(1) Creation date for Preferred Terms, plus additional history notes. May also include scope notes describing how the Preferred Term is indexed.

(2) Applies to Preferred Terms only. Three possible values: MeSH descriptor, device trade name or drug trade name.

(3) Disease term, drug term device term or medical term.

DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 BIB ABS; D L1 TI,AU,SO,CS,AB. The fields are displayed in the order specified.

Hit-term highlighting is available for all searchable fields. Highlighting must be ON during SEARCH to use the HIT, HITIND, KWIC, and OCC formats.

Format	Content	Examples
AB	Abstract	D AB L4 1-5
AN (1)	Accession Number	D AN 1-15
AU	Author	D AU 5 6 8-10
AUPB (2,4)	Authors in Publication Order	D AUPB
CN (TN) (1)	Chemical Name (Drug Trade Name)	D CN L1
CO (1)	Corporate Name (Manufacturer)	D 1-6 L2 CO
CP	Copyright MEDLINE (for unique MEDLINE records only)	D 1 AN CP
CS	Corporate Source	D CS L11
CT (1)	Controlled Term	D CT 1-17
CY	Country of Publication (ISO names)	D 1-7 CY
DN (2)	Document Number	D DN
DOI (FTDOI)	Digital Object Identifier	D DOI or D FTDOI
DT (TC)	Document Type	D DT 4-18 L3
ED (UP)	Entry Date	D ED, D UP
ED.FIR (1,2)	Entry Date First Appeared in Embase or Embase Alert (EMBAL) includes ED (UP)	D ED.FIR
EML (2)	Email Address	D EML
FS	File Segment	D FS 1-2
FTDOI (2)	Digital Object Identifier	D DOI
GEN (1)	Gene Number	D GEN
ISN (2)	International Standard (Document) Number	D 5,6 ISN
JT (2)	Journal Title	D JT
JTA (2)	Journal Title, Abbreviated	D JTA
JTF (2)	Journal Title, Full	D JTF
LA	Language	D LA 4 6 10
MD (2)	Meeting Date	D MD
ML	Meeting Location	D ML
MO	Meeting Organizer	D MO
MT	Meeting Information	D MT
MY	Meeting Year	D MY
NCT	Clinical Trial Numbers	D NCT
NP (1)	Name of Product	D NP
PB	Publisher	D PB
PD (2)	Publication Date	D PD
PUI	Publisher Item Identifier	D PUI
PY (2)	Publication Year	D JT PY
RN (1)	CAS Registry Number	D RN 1-15 L2
SL	Summary Language	D SL 1-5
SO	Source	D 5 L3 SO
ST	Supplementary Terms	D ST
TI (1)	Title	D TI 50-70
ABS	AB	D ABS 1-10
ALL	AN, CP, TI, AU, CS, SO, DOI, PB, PUI, CY, DT, FS, NCT, LA, SL, ED (UP), AB, CT, ST, RN, CN, NP, CO, GEN	D ALL 5-10
AU.CS	AU, CS (grouped in pairs)	D AU.CS
BIB	AN, CP, TI, AU, CS, SO, DOI, PB, PUI, CY, DT, FS, NCT, LA, SL, ED (UP) (BIB is the default)	D BIB 1-10
CBIB	AN, compressed bibliographic data	D CBIB
DALL	ALL, delimited for post-processing	D DALL
IABS	AB, with text labels	D IABS
IALL	ALL, indented with text labels	D IALL
IBIB	BIB, indented with text labels	D IBIB
IND (1)	CT, ST, RN, CN, NP, CO, GEN	D IND L2 1-10

DISPLAY and PRINT Formats (cont'd)

Format	Content	Examples
SCAN (1,3) TRIAL (TRI, FREE, SAM) (1)	TI, CT, ST, RN, CN, NP, CO, GEN (random display without answer numbers) TI, CT, ST, RN, CN, NP, CO, GEN	D SCAN D 1-3 TRIAL
HIT HITIND (1) KWIC OCC (1)	Fields containing hit terms IND Hit term with 20 words on either side (KeyWord-In-Context) Number of occurrences of hit terms and fields in which they occur	D HIT 5-10 D HITIND D KWIC 1-3 D OCC 1-6

(1) No online display fee for this format.

(2) Custom display only.

(3) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.

(4) If 100 or more authors are provided, only the first 99 are presented followed by et al.

SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Abstract	AB	Y	N
Author	AU	Y	Y
Authors in Publication Order	AUPB	Y (8)	N
CAS Registry Number	RN	Y (2)	N
Chemical Name (Drug Trade Name)	CN (TN)	Y	Y
	NAME	Y (2)	N
Chemical Name and CAS Registry Number	CHEM	Y (2)	N
Citation	CIT	Y (3,4)	N
Clinical Trial Numbers	NCT	Y	Y
CODEN	CODEN	N	Y
Controlled Term	CT	Y	N
Corporate Name (Manufacturer)	CO	Y	Y
Corporate Source	CS	Y	Y
Country of Publication	CY	Y	Y
Document Number	DN	N	Y
Document Type	DT	Y	Y
Email Address	EML	Y	N
Entry Date	ED	Y	Y
Entry Date First Appeared in Embase or Embase Alert (EMBAL)	ED.FIR	Y	Y
Entry Date for MEDLINE	EDAL	Y	N
File Segment	FS	Y	Y
Genbank Number	GENBANK	Y (2)	N
Gene Number	GEN	Y	Y
International Standard Book Number	ISBN	N	Y
International Standard (Document) Number	ISN	Y (5)	N
International Standard Serial Number	ISSN	N	Y
Journal Title	JT	Y	Y
Journal Title, Abbreviated	JTA	Y (6)	Y
Journal Title, Full	JTF	Y (6)	Y
Language	LA	Y	Y
Meeting Date	MD	Y	Y

SELECT, ANALYZE, and SORT Fields (cont'd)

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Meeting Information	MT	Y	Y
Meeting Location	ML	Y	Y
Meeting Organizer	MO	Y	Y
Meeting Year	MY	Y	Y
Name of Product	NP	Y	Y
Occurrence Count of Hit Terms	OCC	N	Y
Publication Date	PD	Y	Y
Publication Year	PY	Y	Y
Publisher Item Identifier	PUI	Y	Y
Source	SO	Y (7)	N
Summary Language	SL	Y	Y
Supplementary Terms	ST	Y	N
Title	TI	Y (default)	Y
Trade Name	TN	Y	Y
Treatment Code	TC	Y	Y
Update Date	UP	Y	N
Update Date for MEDLINE	UPAL	Y	N

- (1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT RN.
- (2) Appends /BI to the terms created by SELECT.
- (3) SELECT HIT and ANALYZE HIT are not valid with this field.
- (4) Extracts the first author, publication year, volume, and first page with a truncation symbol appended and /RE appended to the terms created by SELECT.
- (5) Selects or analyzes ISSN, ISBN, and CODEN with /ISN appended to the terms created by SELECT.
- (6) Appends /JT to the terms created by SELECT.
- (7) Selects or analyzes ISSN, ISBN, and CODEN with /SO appended to the terms created by SELECT.
- (8) Appends /AU to the terms created by SELECT.

Sample Records**DISPLAY IALL**

ACCESSION NUMBER: 2013392941 LEMBASE Full-text

TITLE: The role of anti-smoking legislation on cigarette and alcohol consumption habits in Italy.

AUTHOR: Pieroni, Luca (correspondence)

CORPORATE SOURCE: Department of Economics, Finance and Statistics, University of Perugia, via Pascoli 20, 06123 Perugia, Italy. lpieroni@unipg.it

AUTHOR: Pieroni, Luca (correspondence)

CORPORATE SOURCE: University of the West of England, United Kingdom. lpieroni@unipg.it

AUTHOR: Chiavarini, Manuela; Minelli, Liliana; Salmasi, Luca

CORPORATE SOURCE: Department of Medical and Surgery Specialities and Public Health, Division of Public Health, University of Perugia, via del Giochetto, 06123 Perugia, Italy. lminelli@unipg.it; luca.salmasi@progetti.unipg.it; chiavarini@inwind.it

SOURCE: Health Policy, (July 2013) Vol. 111, No. 2, pp. 116-126. Refs: 29

ISSN: 0168-8510; E-ISSN: 1872-6054 CODEN: HEPOEO

DIGITAL OBJECT ID: 10.1016/j.healthpol.2013.04.001

PUBLISHER: Elsevier Ireland Ltd, P.O. Box 85, Limerick, Ireland.

PUBLISHER IDENT.: S 0168-8510(13)00098-5

COUNTRY: Ireland

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
036 Health Policy, Economics and Management

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered Embase: 2 Jul 2013

Last Updated on Embase: 2 Jul 2013

First Entered Embase or Embase Alert: 3 May 2013

ABSTRACT: The short-term effects of public smoking bans on individual smoking and drinking habits were investigated in this paper. In 2005, a smoking ban was introduced in Italy, and we exploited this exogenous variation to measure the effect on both smoking participation and intensity and the indirect effect on alcohol consumption. Using data from the Everyday Life Aspects survey, for the period 2001-2007, we show that the introduction of smoke-free legislation in Italy significantly affected smoking behavior. We also document significant indirect effects on alcohol consumption for the main alcoholic beverage categories. A robustness analysis is also performed, to test the extent to which unobservable variables may bias our estimated parameters. Our results are then used to perform a cost-effectiveness analysis of the anti-smoking legislation in Italy. © 2013.

CONTROLLED TERM: Medical Descriptors:
*alcohol consumption
article
cost effectiveness analysis
female
health care policy
human
Italy
male
*smoking ban

SUPPLEMENTARY TERM: Anti-smoking legislation; Cost-effectiveness analysis;
Difference-in-Differences; Regression discontinuity

DISPLAY of a Conference Abstract

AN 0050751984 LEMBASE
TI Abl tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages.
AU Stenger, S. (correspondence); Bruns, H.; Stegelmann, F.; Dohner, K.; Van Zandbergen, G.
CS Medizinische Mikrobiologie und Hygiene Ulm, Germany.
AU Ficker, J.H.; Wagner, M.
CS Klinikum Nurnberg Nord, Germany.
SO Pneumologie, (March 2011) Vol. 65, Suppl. SUPPL. 1. Abstract Number: V479.
Meeting Info: 52. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.. Dresden, Germany. 07 Apr 2011-10 Apr 2011
ISSN: 0934-8387
PB Georg Thieme Verlag.
DT Journal; Conference; (Conference Abstract)
FS CONF
LA English
SL English
ED Entered STN: Sep 2012
Last Updated on STN: Sep 2012
AB The mechanisms that regulate the acidification of intracellular compartments are key to host defense pathways against intracellular pathogens. Here we demonstrate that Abl tyrosine kinase, a master switch for cell growth, cell survival and trafficking of organelles, controls the acidification of lysosomes and phagosomes. Inhibition of Abl tyrosine kinase by imatinib, a molecular targeted therapy used as standard treatment for chronic myeloid leukemia reduced the lysosomal pH in macrophages. This pH-shift was functionally relevant because imatinib increased the activity of the proteolytic enzyme cathepsin D and limited the growth of the major human pathogen Mycobacterium tuberculosis. These effects were active in vivo because acidic monocytes were more readily detectable in the blood of imatinib-treated leukaemia patients than in healthy controls. Given that inhibition of Abl tyrosine kinase enhances macrophage antimycobacterial activity, imatinib or similar antagonists have the potential to complement conventional drug therapy of multidrug- or extremely drug resistant tuberculosis.

LEMBASE**DISPLAY of a Embase Alert Record**

AN 2013392941 LEMBASE Full-text
 TI The role of anti-smoking legislation on cigarette and alcohol consumption habits in Italy.
 AU Pieroni, Luca (correspondence)
 CS Department of Economics, Finance and Statistics, University of Perugia, via Pascoli 20, 06123 Perugia, Italy. lpieroni@unipg.it
 AU Pieroni, Luca (correspondence)
 CS University of the West of England, United Kingdom. lpieroni@unipg.it
 AU Chiavarini, Manuela; Minelli, Liliana; Salmasi, Luca
 CS Department of Medical and Surgery Specialities and Public Health, Division of Public Health, University of Perugia, via del Giochetto, 06123 Perugia, Italy. lminelli@unipg.it; luca.salmasi@progetti.unipg.it; chiavarini@inwind.it
 SO Health Policy, (July 2013) Vol. 111, No. 2, pp. 116-126.
 Refs: 29
 ISSN: 0168-8510; E-ISSN: 1872-6054 CODEN: HEPOEO
 PB Elsevier Ireland Ltd, P.O. Box 85, Limerick, Ireland.
 PUI S 0168-8510(13)00098-5
 CY Ireland
 DT Journal; Article
 FS 017 Public Health, Social Medicine and Epidemiology
 036 Health Policy, Economics and Management
 LA English
 SL English
 ED Entered Embase: 2 Jul 2013
 Last Updated on Embase: 2 Jul 2013
 First Entered Embase or Embase Alert: 3 May 2013

DISPLAY TRIAL

TI Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data.
 CT Medical Descriptors:
 adult
 article
 attributable risk
 billing and claims
 confidence interval
 cost of illness
 data base
 device
 *drug delivery system
 drug dosage form comparison
 emergency ward
 evaluation
 female
 health care cost
 health care planning
 health care utilization
 health economics
 hospital cost
 human
 hypoglycemia: SI, side effect
 incidence
 information processing
 insulin treatment
 major clinical study
 male
 managed care
 medical practice
 morbidity
 *non insulin dependent diabetes mellitus: DM, disease management
 *non insulin dependent diabetes mellitus: DT, drug therapy

outpatient care
*patient compliance
resource allocation
retrospective study
statistical analysis
statistical significance
syringe
treatment duration
treatment outcome
United States
CT Drug Descriptors:
*insulin aspart: AE, adverse drug reaction
*insulin aspart: AD, drug administration
*insulin aspart: DT, drug therapy
*insulin aspart: PR, pharmaceuticals
*insulin aspart: PE, pharmacoconomics
ST adherence; cost; diabetes; FlexPen; hypoglycemia; insulin pen; outcomes
RN (insulin aspart) 116094-23-6
CN (1) novolog
CO (1) Novo Nordisk (United States)
NP (1) FlexPen
CO (1) Novo Nordisk (United States)

In North America

CAS
STN North America
P.O. Box 3012
Columbus, Ohio 43210-0012 U.S.A.

CAS Customer Center:
Phone: 800-753-4227 (North America)
614-447-3700 (worldwide)
Fax: 614-447-3751
Email: help@cas.org
Internet: www.cas.org

In Europe

FIZ Karlsruhe
STN Europe
P.O. Box 2465
76012 Karlsruhe
Germany
Phone: +49-7247-808-555
Fax: +49-7247-808-259
Email: helpdesk@fiz-karlsruhe.de
Internet: www.stn-international.com

In Japan

JAICI (Japan Association for
International Chemical Information)
STN Japan
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021, Japan
Phone: +81-3-5978-3601 (Technical Service)
+81-3-5978-3621 (Customer Service)
Fax: +81-3-5978-3600
Email: support@jaici.or.jp (Technical Service)
customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp